inthyroid-hormone binding capacity. Inneither kit forfree triiodothyronine was theequilibrium between bound and free hormone significantly disturbed duringassay.Overall, as a diagnostic indexofthyroid status, free trilodothyronine is as good as thefree triiodothyronine index and better than either triiodothyronine or the triiodothyronine/thyroxin-binding globulin ratio. Coat-A-Count" F'T3 kits2 and compare their diagnostic effectiveness with those of T3, T3/TBG, and the free T3 index.
Materials and Methods

Procedures
In all sera we measured total thyroxin, free thyroxin, thyroxiniTBG, free thyroxin index, T3, FF3, T31TBG, free T3 index, TBG, and T3 uptake ratio. TBG was determined with the "Imniophase RIA" test system (Corning Medical and Scientific, Medfield, MA 02052), and T3 uptake was estimated with the "MAA" kit (Amersham International).
The thyroxiniTBG ratio was calculated by dividing total thyroxin by the TBG concentration. Similarly, the T31TBG ratio was obtained by dividing total T3 by the TBG concentration. T3 uptake was expressed as the ratio of sample percent uptake to the percent uptake in a control serum (T3 uptake ratio). The free thyroxin index was computed by multiplying total thyroxin by the T3 uptake ratio and, similarly, the free T3 index by multiplying total T3 by the T3 uptake ratio.
Arnerlex.
FT3 concentration
was estimated by following the directions recommended by the supplier. Patients' sera were incubated for 2 h at 37 #{176}C with anti-T3-antibody bound to Amerlex particles and 1251-labeled T3 analog tracer that binds to high-affinity antiserum but not to proteins that bind thyroid hormone.
At the end of the incubation period, the tubes were centrifuged, the supernates decanted, and the radioactivity of the pellets was measured. FF3 concentration was estimated by comparing the activity m the pellet with that in a standard curve similarly prepared for FF3.
Pre-release
Coat-A -Count. FT3 concentration was estimated by following the directions recommended by the manufacturer.
Patients' sera were incubated for 3 h at 37 #{176}C with I '2511T3 tracer in 1 .0-mL of assay buffer in tubes coated with anti-T3 antibody. The role of 1125IJT3 specific tracer is to act as an indicator of the distribution of endogenous T3 between the binders, because T3 tracer will distribute itself within the equilibrium system in exactly the same manner as endogenous T3.
Therefore the fraction of tracer bound to the antisera will be equivalent to the fraction of endogenous T3 bound to the antisera. Hence it represents the amount of serum T3 bound by the antisera during the assay.
Patients
To determine thyroid status, we used measurements of the free thyroxin index followed by assay of serum thyrotropin or of thyrolibenn All of the latter eight subjects were found on subsequent detailed examination to be clinically euthyroid, the TBG deficiency being due to a non-thyroidal illness or of unknown cause. Sixteen subjects (seven men, nine women) being treated with phenythin, either exclusively or in combination with other anticonvulsants.
degree of linear association among the different variables, Student's t-statistics for tests on regression coefficients (9) , and the unpaired t-test for comparing means of different determinations with normal control mean values, for the various groups under study. A p value of 0.05 was considered significant.
Results and Discussion
Performance Characteristics of FT3 kits reported similar values for the lower limit of the reference range but found a much higher upper limit of normal.
Precision. For both kits, equilibrium had still not been attained after 4 h.
Intermethod
comparison.
There was a high correlation (r Effect of FT3 kit antisera on the serum equilibrium system during assay. A problem in measuring FF3 (or free thyroxin) in a single tube is that while only a small part of the free fraction must be removed from the serum system if one is not to disrupt the equilibrium, adequate assay sensitivity must be maintained.
High sensitivity can be achieved by using a very high avidity antiserum. We found that sensitivities for both FF3 assays exceeded that required for determination of serum FF3 (the minimal detectable concentrations for Amerlex FF3 and Coat-A-Count FF3 were 0.4 and 0.6 pmollL, respectively). Published affinities (Ka) of TBG, the strongest thyroid hormone binder, for T3 in blood range from 2.5 x 108 to 5.4 x i08 L/mo! (19) (20) (21) (22) .
We calculated the average affinities of Amerlex and Coat-ACount antisera for T3 to be 4.6 x i#{248} and 1.4 x i09 L/mol, respectively, on using the approach based on the Scatchard plot (23) as introduced for radioimmunoassay by Berson and Yalow (24) . Thus in both FF3 kits the antibody has a higher avidity for T3 than that of TBG for T3. Whan can happen therefore is that these high-affinity antisera will attract bound T3 with a power greater than that which can be resisted by the binding capacity of the thyroid hormonebinding proteins in serum (25) . If as a result too much T3 is removed from the serum system, the equilibrium between bound and free hormone will be significantly disturbed and the assay will no longer correctly measure FT3 concentration.
We performed an experiment in which we measured the percentage of serum T3 bound to antisera at the end of the incubation period for serum samples, I12S]fJ3 non-analog tracer, and antisera from each Ff3 kit, to determine how much T3 is removed from the serum system during assay. A similar experiment was used by Amersham to calculate the percent thyroxin displaced from serum binding proteins in their Amerlex free thyroxin assay (26) . In our study the Amerlex FF3 kit and the Coat-A-Count FF3 kit, respectively, shdwed a mean percentage pickup by the antisera of 11.8 ± 1.2% and 10.6 ± 1.0% in sera from 15 euthyroid women with normal thyroid hormone binding capacity. By comparison, in several free thyroxin kit methods, less than 5% of serum thyroxin is bound to the antisera during assay (26, 27) . We also found that binding of T3 by the antisera in both FF3 assays was low in pregnant women and hyperthyroid patients and high in TBG-deficient patients and hyperthyroid subjects as compared with normal. Theoretical and experimental analyses showed that these trends were similar to those findings in free thyroxin kits in which the analog method is used (26, 28 T3 progressively increased during pregnancy, paralleling the increase in TBG. By the third trimester the mean T3 concentration was 150% of the non-pregnant reference mean and the mean TBG concentration had increased even more, to 218% of the non-pregnant mean. The net result was a decline in T3PFBG. T3/"FBG misclassified a substantial proportion (60%) of third-trimester pregnant patients as hypothyroid. FF3 followed the descending changes in T3,TBG, as predicted by Whitworth et al. (29) . 
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tively, of the non-pregnant mean. However, no more than two (10%) patients had FF3 concentrations in the hypothyroid range. Similar decreases in FF3 concentrations with duration of pregnancy have been reported by others (30) . We found only a slight increase in free T3 index with advancing pregnancy; only two patients (10%) gave high values for the free T3 index in the third trimester.
Parslow et al. (31) indicated that a determination of this index will correct for variations in TBG concentration due to pregnancy; another study (7) showed that values for the free T3 index in the third trimester were significantly lower than control. These differences reported between studies, however, are probably related to the type of T3 uptake tests used (32) .
These results indicate that, in pregnancy, values by either FF3 kit and free T3 index are better indices of thyroid status than are data on the T3/TBG ratio. and chose it because of its superior precision and marginally better overall diagnostic accuracy. FF3 did not have any obvious advantages over the estimation of free T3 index as an index of thyroid status but potentially could replace either T3 or T3/TBG as a more reliable diagnostic test of thyroid function.
The "Pre-release Coat-A-Count" RIA FF3 kits were supplied without cost by Bio-Mediq Pty. Ltd., by courtesy of Mr. Kevin Walsh.
